Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Polidocanol for In-Transit and Cutaneous Melanoma Metastases
NCT03754140Phase 2Withdrawn
- Sponsor
- Melanoma Institute Australia
- Start
- May 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 10XB101 in melanoma, sponsored by Melanoma Institute Australia. Planned start May 2020; status: withdrawn.
02
Drugs
10XB101
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03754140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03754140.